Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines

Anti-Cancer Drugs

Volumn 17, Issue 6, 2006, Pages 657-662

  Lanvers Kaminsky, Claudia ^a   Bremer, Alexis ^a   Dirksen, Uta ^a   Jürgens, Heribert ^a   Boos, Joachim ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Busulfan; Ewing tumor; High dose chemotherapy; Neuroblastoma; Treosulfan

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BUSULFAN; TREOSULFAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL VIABILITY; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG MEGADOSE; EWING SARCOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NEUROBLASTOMA; NEUROBLASTOMA CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; BUSULFAN; CELL SURVIVAL; HUMANS; LEUKEMIA; NEUROBLASTOMA; OSTEOSARCOMA; SARCOMA, EWING'S; TUMOR CELLS, CULTURED;

EID: 33747598242     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000215059.93437.89     Document Type: Article

References (36)

1. Burdach S, Jurgens H. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 2002; 41:169-189.
2. Ladenstein R, Philip T, Gardner H. Autologous stem cell transplantation for solid tumors in children. Curr Opin Pediatr 1997; 9:55-69.
3. Philip T, Ladenstein R, Lasset C, Hartmann O, Zucker JM, Pinkerton R, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997; 33:2130-2135.
4. Hartmann O, Valteau-Couanet D, Benhamou E, Vassal G, Rubie H, Beaujean F, et al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 1997; 33:2126-2129.
5. Ladenstein R, Lasset C, Pinkerton R, Zucker JM, Peters C, Burdach S, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15:697-705.
6. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 2003; 40:276-287.
7. Feit PW. Stereoisomere 1,4-di-O-methansulfonoyl-butan-1,2,3,4-tetrole. Tetrahedron Lett 1961; 20:716-717.
8. Feit PW, Nielsen OT. Alkylating agents related to 2,2′-biaziridine. I. Compounds derived from 1,4-diamino-2,3-butanediol. J Med Chem 1967; 10:697-700.
9. Feit PW, Rastrup-Andersen N, Matagne R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate. J Med Chem 1970; 13:1173-1175.
10. Feit PW, Rastrup-Andersen N. 4-Methanesulfonyloxybutanol: hydrolysis of busulfan. J Pharm Sci 1973; 62:1007-1008.
11. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 1999; 79:264-266.
12. Hassan M, Ehrsson H. Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 1983; 277:374-380.
13. Kopf-Maier P, Sass G. Antitumor activity of treosulfan against human breast carcinomas. Cancer Chemother Pharmacol 1992; 31:103-110.
14. Kopf-Maier P, Sass G. Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol 1996; 37:211-221.
15. Kopf-Maier P. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro. In Vivo 1998; 12:275-288.
16. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79:1487-1493.
17. Neuber K, Tom DA, Blodorn-Schlicht N, Itschert G, Karnbach C. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Melanoma Res 1999; 9:125-132.
18. Reber U, Wullner U, Trepel M, Baumgart J, Seyfried J, Klockgether T, et al. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2. Biochem Pharmacol 1998; 55:349-359.
19. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6:4209-4216.
20. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35:233-241.
21. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103:725-731.
22. Koenigsmann M, Mohren M, Jentsch-Ullrich K, Franke A, Becker E, Heim M, et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 2004; 34:477-483.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
24. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods 1986; 93:157-165.
25. Matagne R. Induction of chromosomal aberrations and mutations with isomeric forms of L-threitol-I,4-bismethanesulfonate in plant materials. Mutat Res 1969; 7:241-247.
26. Ponti M, Souhami RL, Fox BW, Hartley JA. DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates. Br J Cancer 1991; 63:743-747.
27. Bosanquet AG, Burlton AR. Airborne cytotoxicity in the DiSC assay caused by solutions of treosulfan but not busulphan. Cytotechnology 1994; 16:131-136.
28. Ehrsson H, Hassan M. Determination of busulfan in plasma by GC-MS with selected-ion monitoring. J Pharm Sci 1983; 72:1203-1205.
29. Fichtner I, Becker M, Baumgart J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 2003; 39:801-807.
30. Loeb V Jr. Dihydroxybusulfan (NSC-39069) in chronic myelocytic leukemia and miscellaneous malignant neoplasms. Cancer Chemother Rep 1964; 42:39-43.
31. Brodsky R, Topolsky D, Crilley P, Bulova S, Brodsky I. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol 1990; 13:221-225.
32. Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant 1998; 22:1191-1197.
33. Jones TR, Humphrey PA, Brennan DC. Transplantation of vascularized allogeneic skeletal muscle for scalp reconstruction in a renal transplant patient. Transplantation 1998; 65:1605-1610.
34. Barnes JR, Ranta KE. The metabolism of dimethylformamide and dimethylacetamide. Toxicol Appl Pharmacol 1972; 23:271-276.
35. Kim SN. Preclinical toxicology and pharmacology of dimethylacetamide, with clinical notes. Drug Metab Rev 1988; 19:345-368.
36. Weiss AJ, Jackson LG, Carabasi RA, Mancall EL, White JC. A phase I study of dimethylacetamide. Cancer Chemother Rep 1962; 16:477-485.